129 related articles for article (PubMed ID: 11306724)
1. Clinical significance of occult metastatic cells in bone marrow of breast cancer patients.
Braun S; Pantel K
Oncologist; 2001; 6(2):125-32. PubMed ID: 11306724
[TBL] [Abstract][Full Text] [Related]
2. Molecular markers of metastasis in breast cancer: current understanding and prospects for novel diagnosis and prevention.
Braun S; Harbeck N
Expert Rev Mol Med; 2001 Sep; 3(22):1-14. PubMed ID: 14585146
[TBL] [Abstract][Full Text] [Related]
3. Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer.
Braun S; Rosenberg R; Thorban S; Harbeck N
Semin Surg Oncol; 2001 Jun; 20(4):334-46. PubMed ID: 11747276
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of micrometastatic bone marrow involvement.
Braun S; Pantel K
Breast Cancer Res Treat; 1998; 52(1-3):201-16. PubMed ID: 10066083
[TBL] [Abstract][Full Text] [Related]
5. Micrometastatic bone marrow involvement: detection and prognostic significance.
Braun S; Pantel K
Med Oncol; 1999 Sep; 16(3):154-65. PubMed ID: 10523795
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of occult metastatic cells in the bone marrow of patients with different stages of breast cancer.
Janni W; Rjosk D; Braun S
Clin Breast Cancer; 2000 Oct; 1(3):217-25. PubMed ID: 11899646
[TBL] [Abstract][Full Text] [Related]
7. Molecular determinants of occult metastatic tumor cells in bone marrow.
Pantel K; Braun S
Clin Breast Cancer; 2001 Oct; 2(3):222-8. PubMed ID: 11899416
[TBL] [Abstract][Full Text] [Related]
8. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
Braun S; Müller M; Hepp F; Schlimok G; Riethmüller G; Pantel K
J Natl Cancer Inst; 1998 Jul; 90(14):1099-101. PubMed ID: 9672259
[No Abstract] [Full Text] [Related]
9. [Immunocytochemical detection and prognostic significance of epithelial tumor cells in bone marrow of patients with pancreatic carcinoma].
Thorban S; Roder JD; Pantel K; Siewert JR
Zentralbl Chir; 1996; 121(6):487-9; discussion 490-2. PubMed ID: 8767337
[TBL] [Abstract][Full Text] [Related]
10. Biological characteristics of micrometastatic cancer cells in bone marrow.
Braun S; Pantel K
Cancer Metastasis Rev; 1999; 18(1):75-90. PubMed ID: 10505547
[TBL] [Abstract][Full Text] [Related]
11. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
[TBL] [Abstract][Full Text] [Related]
12. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients.
Watson MA; Ylagan LR; Trinkaus KM; Gillanders WE; Naughton MJ; Weilbaecher KN; Fleming TP; Aft RL
Clin Cancer Res; 2007 Sep; 13(17):5001-9. PubMed ID: 17785550
[TBL] [Abstract][Full Text] [Related]
13. [Study of bone marrow changes using marrow immunography].
Carrió Gasset I; Berná Roqueta L
Sangre (Barc); 1997 Aug; 42(4):295-9. PubMed ID: 9381286
[No Abstract] [Full Text] [Related]
14. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow.
Braun S; Hepp F; Kentenich CR; Janni W; Pantel K; Riethmüller G; Willgeroth F; Sommer HL
Clin Cancer Res; 1999 Dec; 5(12):3999-4004. PubMed ID: 10632331
[TBL] [Abstract][Full Text] [Related]
15. [The prognostic significance of tumor cell detection in bone marrow of patients with breast cancer].
Diel IJ; Kaufmann M; Costa SD; Kaul S; Krempien B; Goerner R; Bastert G
Geburtshilfe Frauenheilkd; 1990 Dec; 50(12):923-8. PubMed ID: 1707840
[TBL] [Abstract][Full Text] [Related]
16. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
17. Immunodiagnosis and immunotherapy of isolated tumor cells disseminated to bone marrow of patients with colorectal cancer.
Braun S; Pantel K
Tumori; 1995; 81(3 Suppl):78-83. PubMed ID: 7571061
[TBL] [Abstract][Full Text] [Related]
18. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
Braun S; Schlimok G; Heumos I; Schaller G; Riethdorf L; Riethmüller G; Pantel K
Cancer Res; 2001 Mar; 61(5):1890-5. PubMed ID: 11280743
[TBL] [Abstract][Full Text] [Related]
19. No effect of timing of biopsy in the menstrual cycle on incidence of bone marrow micrometastasis in patients with breast cancer.
Singhal H; Potter C; Osborne MP
Ann Surg Oncol; 1997 Sep; 4(6):503-5. PubMed ID: 9309341
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow micrometastases do not impact disease-free and overall survival in early stage sentinel lymph node-negative breast cancer patients.
Langer I; Guller U; Worni M; Berclaz G; Singer G; Schaer G; Fehr MK; Hess T; Viehl C; Bronz L; Schnarwyler B; Wight E; Infanger E; Burger D; Koechli OR; Zuber M;
Ann Surg Oncol; 2014 Feb; 21(2):401-7. PubMed ID: 24145993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
